Focusing on novel AI-based digital diagnostics and therapeutics solutions for brain health
Developing BRAIN AGE™, an electroencephalogram-based (EEG) artificial intelligence solution to detect an individual’s brain age for clinical and home use
TORONTO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED), an artificial intelligence driven digital diagnostics and therapeutics company for brain health, is pleased to announce that its common shares have been approved for listing on the Canadian Securities Exchange (the “CSE”). The Company expects to commence trading on Tuesday, November 8, under the trading symbol “DMED” at market open.
“I would like to thank our team and advisors for their efforts in achieving our CSE listing, and a special thanks to our shareholders for their support and confidence in DiagnaMed’s goal to commercialize digital diagnostics and therapeutics for brain health,” said Fabio Chianelli, Founder and Chairman of the Board of DiagnaMed. “Our main focus is the development of BRAIN AGE™, an electroencephalogram-based (EEG) artificial intelligence solution to detect an individual’s brain age for clinical and home use, which we expect to make commercially available in 2023. We intend to grow our team, and I look forward to updating the investment and medical communities on our developments with BRAIN AGE™ and our product developments.”
For more information and to receive regular news updates from DiagnaMed, visit www.DiagnaMed.com.
About DiagnaMed Holdings Corp.
DiagnaMed Holdings Corp. (CSE: DMED) is an artificial intelligence driven digital diagnostics and therapeutics company focusing on improving brain health for mental health and neurodegenerative disorders. The Company is developing BRAIN AGE™, an electroencephalogram-based (EEG) artificial intelligence solution to detect an individual’s brain age for clinical and home use, and BrainTremor™, a wearable device to detect tremors for Parkinson’s disease and essential tremors. Learn more at DiagnaMed.com.
For more information about DiagnaMed, please contact:
Fabio Chianelli
Chairman of the Board
DiagnaMed Holdings Corp.
Tel: 416-800-2684
Email: info@diagnamed.com
Website: www.diagnamed.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement
Certain statements in this news release are forward-looking statements, including with respect to future plans, and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as “may”, “expect”, “estimate”, “anticipate”, “intend”, “believe” and “continue” or the negative thereof or similar variations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including but not limited to, business, economic and capital market conditions, the ability to manage operating expenses, and dependence on key personnel. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, anticipated costs, and the ability to achieve goals. Factors that could cause the actual results to differ materially from those in forward-looking statements include, the continued availability of capital and financing, litigation, failure of counterparties to perform their contractual obligations, loss of key employees and consultants, and general economic, market or business conditions. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in DiagnaMed's final prospectus dated October 28, 2022, which is available on the Company's profile at www.sedar.com. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.
